[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Challenges in Otolaryngology
March 2003

Genetic Markers in the Clinical Care of Head and Neck CancerSlow in Coming

Author Affiliations
 

KAREN H.CALHOUNMD

 

RONALD B.KUPPERSMITHMD

Arch Otolaryngol Head Neck Surg. 2003;129(3):367-368. doi:10.1001/archotol.129.3.367

In the 1990s, PCR permitted detailed investigation of genetic material. By decade's end, researchers declared that the human genome had been mapped. Tumor-specific genetic alterations were identified amidst great hope for clinically relevant innovation. Dr Friedlander accurately voices the disappointment of many that the utility of biomarkers is "limited to experimental clinical trials." Nearly every new putative marker is examined for clinical relevance. Even those that show promise in small pilot studies seem to fade under the scrutiny of larger, well-designed confirmatory studies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×